Mechanism of action of strontium ranelate: What are the facts?

Clinical Cases in Mineral and Bone Metabolism

Volumn 7, Issue 1, 2010, Pages 17-18

  Fonseca, João Eurico ^a,b   Brandi, Maria Luisa ^c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE;

BONE STRUCTURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FRACTURE; FRACTURE HEALING; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE;

EID: 77953320532     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (21)

1. Zhu LL, Zaidi S, Peng Y, Zhou H, Moonga BS, Blesius A, Dupin-Roger I, Zaidi M, Sun L 2007 Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun 355:307-11. (Pubitemid 46282628)
2. Bonnelye E, Chabadel A, Saltel F, Jurdic P 2008 Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129-38. (Pubitemid 350297175)
3. Atkins GJ, Welldon KJ, Halbout P, Findlay DM 2009 Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653-64.
4. Brennan T, Rybchyn M, Green W, Atwa S, Conigrave A, Mason R 2009 Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157:1291-300.
5. Brennan T, Rizzoli R, Ammann P 2009 The mode of action of strontium ranelate involves the stimulation of IGF-I production and a decrease in signals for osteoclastogenesis in vivo. Abstract OP02. Bone 44:S236.
6. Hurtel-Lemaire AS Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, Terwilliger EF, Brown EM, Brazier M 2009 The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways J Biol Chem 284: 575-84.
7. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012-20. (Pubitemid 41103416)
8. Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P 2009 Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20:1417-28.
9. Marie PJ, Hott M, Modrowski D, De PC, Guillemain J, Deloffre P, Tsouderos Y 1993 An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607-15. (Pubitemid 23127921)
10. Hott M, Deloffre P, Tsouderos Y, Marie PJ 2003 S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 33:115-23. (Pubitemid 36952693)
11. Delannoy P, Bazot D, Marie PJ 2002 Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 51:906-11.
12. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A 2001 Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 29:176-9. (Pubitemid 32734498)
13. Geoffroy V, Chappard D, Libouban H, Pascaretti C, Ostertag A, De Vernejoul MC 2007 Strontium ranelate counteracts the dramatic increase of endocortical resorption in mice with a severe osteoporosis. Abstract P020-M. Calcif Tissue Int 80(suppl 1):S42.
14. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-68. (Pubitemid 38133766)
15. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-22. (Pubitemid 40686329)
16. Marie PJ 2008 Effective doses for strontium ranelate. Osteoporos Int 19:1813.
17. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ 2008 Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215-22. (Pubitemid 351160035)
18. Briot K, Benhamou CL, Roux C 2009 Effect of strontium ranelate on hip structural geometry. Abstract SAT0375. Ann Rheum Dis 68(suppl 3):665.
19. Rizzoli R, Felsenberg D, Laroche M, Seeman E, Krieg MA, Frieling I, Thomas T, Delmas PD 2009 Superiority of strontium ranelate as compared to alendronate on microstructural determinants of bone strength at the distal tibia in women with postmenopausal osteoporosis. Abstract SAT0388. Ann Rheum Dis 68(suppl 3):669.
20. Blake GM, Fogelman I 2006 Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Miner Res. 2006 Sep;21(9):1417-24. (Pubitemid 44300048)
21. Ammann P, Badoud I, Barraud S, Dayer D,Rizzoli R 2007 Strontium ranelate treatment improves trabecular and cortical intrinsic bone quality, a determinant of bone strength. J Bone Miner Res 22:1419-25. (Pubitemid 351339686)